We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
(+1.9%)
Cap. Flow
-$123M
Cap. Flow
% of AUM
-7.84%
Top 10 Holdings %
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$17.2M |
| 2 |
MannKind Corp
MNKD
|
+$15.2M |
| 3 |
Arbutus Biopharma
ABUS
|
+$4.32M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$3.59M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$3.08M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$23.5M |
| 2 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$10.9M |
| 3 |
Gilead Sciences
GILD
|
+$5.35M |
| 4 |
AGEN
Agenus
AGEN
|
+$4.63M |
| 5 |
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
|
+$3.79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 9.13% |
| 2 | Communication Services | 0.29% |
| 3 | Materials | 0.04% |
| 4 | Financials | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CALL
Vertex Pharmaceuticals
VRTX
$124B
| $198M | 12.63% |
26,661
+1,771
| +7% | +$123K |
|
2
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $165M | 10.52% |
+8,933
| New | +$1.58M |
|
|
3
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
| $74.6M | 4.76% |
29,863
+21
| +0.1% | +$495 |
|
|
4
PUT
Vertex Pharmaceuticals
VRTX
$124B
| $72.6M | 4.63% |
9,768
+3,217
| +49% | +$224K |
|
5
CALL
Merck
MRK
$326B
| $64.2M | 4.1% |
13,448
-4,638
| -26% | -$212K |
|
|
AGN
6
CALL
DELISTED
Allergan Inc
AGN
| $62.1M | 3.96% |
5,589
+3,049
| +120% | +$291K |
|
7
CALL
iShares S&P 100 ETF
OEF
$19.8B
| $57.7M | 3.68% |
5,000
+750
| +18% | +$59.3K |
|
|
8
PUT
Gilead Sciences
GILD
$167B
| $51.2M | 3.26% |
6,808
-1,698
| -20% | -$118K |
|
9
CALL
Bristol-Myers Squibb
BMY
$130B
| $50.5M | 3.22% |
9,493
+3,354
| +55% | +$171K |
|
|
10
PUT
Teva Pharmaceuticals
TEVA
$36.9B
| $34.1M | 2.17% |
8,505
+7,555
| +795% | +$297K |
|
11
CALL
GSK
GSK
$108B
| $33.6M | 2.14% |
5,040
-185
| -4% | -$12K |
|
|
MDVN
12
PUT
DELISTED
MEDIVATION, INC.
MDVN
| $31.4M | 2% |
9,836
| – | – |
|
13
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $28.2M | 1.8% |
+4,328
| New | +$184K |
|
14
CALL
Biogen
BIIB
$30.4B
| $25.3M | 1.61% |
903
+29
| +3% | +$7.5K |
|
|
15
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $24.7M | 1.58% |
1,338
-912
| -41% | -$161K |
|
|
CBST
16
PUT
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $23.2M | 1.48% |
3,370
+3,308
| +5,335% | +$214K |
|
|
17
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $23.1M | 1.47% |
2,000
-3,728
| -65% | -$295K |
|
|
18
MannKind Corp
MNKD
$1.21B
| $20.5M | 1.31% |
786,370
+599,566
| +321% | +$15.2M |
|
|
19
Teva Pharmaceuticals
TEVA
$36.9B
| $18.7M | 1.19% |
466,312
+437,709
| +1,530% | +$17.2M |
|
|
AGN
20
PUT
DELISTED
Allergan Inc
AGN
| $18M | 1.14% |
1,616
-417
| -21% | -$39.8K |
|
21
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
| $17.9M | 1.14% |
652
-349
| -35% | -$100K |
|
22
CALL
Opko Health
OPK
$1.25B
| $16.5M | 1.05% |
19,558
+526
| +3% | +$5.32K |
|
|
23
CALL
MannKind Corp
MNKD
$1.21B
| $15.9M | 1.02% |
6,118
-908
| -13% | -$23.1K |
|
24
PUT
Sarepta Therapeutics
SRPT
$1.63B
| $15.2M | 0.97% |
7,473
-5,555
| -43% | -$165K |
|
|
25
CALL
Gilead Sciences
GILD
$167B
| $15M | 0.96% |
2,000
-500
| -20% | -$34.8K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q4 2013 Portfolio in Review
As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.
Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.
- Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
- Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
- Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
- Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
- Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
- Sabby Management opened 83 new positions and closed 62 in Q4 2013.
- Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.
Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.